Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

196

Full text

162

Free full text

Publication Types

Journal Article

200

Research Support, Non-U.S. Gov't

Review

Randomized Controlled Trial

Multicenter Study

Observational Study

Research Support, N.I.H., Extramural

Comparative Study

Clinical Trial

Clinical Trial, Phase I

Clinical Trial, Phase III

Case Reports

Meta-Analysis

Clinical Trial, Phase II

Letter

News

Systematic Review

Equivalence Trial

Research Support, N.I.H., Intramural

Research Support, U.S. Gov't, Non-P.H.S.

Comment

Evaluation Study

Historical Article

Network Meta-Analysis

Scoping Review

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""HIV Integrase Inhibitors""[mesh_terms]

206 Results

Searching titles within these results

Raltegravir penetration in seminal plasma of healthy volunteers.

Giovanni Di Perri, Daniel Gonzalez de Requena, Mattia Chiesa, Marco Simiele, Marco Siccardi, Antonio D'Avolio, Stefano Bonora, Andrea Calcagno

Antimicrobial agents and chemotherapy 2010;54(6):2744-5

Free Full Text

A safety evaluation of raltegravir for the treatment of HIV.

Rosa de Miguel, Rocio Montejano, Natalia Stella-Ascariz, Jose R Arribas

Expert opinion on drug safety 2018;17(2):217-223

Full Text

Abstract

The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience.

G Mathé

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2000;54(1):3-6

Full Text

Abstract

Integrase strand transfer inhibitors, their impact in adipose tissue and weight gain in people living with HIV - A narrative review.

Ericka Nelly Pompa-Mera, Jesús E Gaytán-Martínez, Mireya Núñez-Armendáriz, María Magdalena Valle-Hernández, José Antonio Mata-Marín, Elba Reyes-Maldonado

Nutricion hospitalaria 2025;43(3):572-578

Free Full Text

Abstract

Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Alan N Engelman

The Journal of biological chemistry 2020;294(41):15137-15157

Free Full Text

Abstract

The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.

Daniel Elbirt, Hila Elinav, Keren Mahlab-Guri, Ofer Perzon, Omer Maman, Wiessam Abu Ahmad

BMC infectious diseases 2024;24(1):221

Free Full Text

Abstract

Targeting the HIV integration process in antiviral therapy.

Melissa McNeely, Frauke Christ, Wannes Thys, Zeger Debyser

Journal of HIV therapy 2009;13(4):83-92

Full Text

Raltegravir in treatment naive patients.

F Cossarini, A Castagna, Adriano Lazzarin

European journal of medical research 2010;14 Suppl 3(Suppl 3):22-9

Free Full Text

Abstract

Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches.

Daniele Santoni, Maria Mercedes Santoro, Francesca Ceccherini-Silberstein, Roberta Gagliardini, Carlo Federico Perno, Federica Forbici, William Gennari, Ada Bertoli, Luca Carioti, Lavinia Fabeni, Saverio Lemme, Yagai Bouba, Davide Vergni

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2022;101():105294

Free Full Text

Abstract

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.

Claire L Townsend, Martina Penazzato, Françoise Renaud, Valériane Leroy, Julie Jesson, Marissa Vicari, Hannah Castro, Ali Judd, Intira Jeannie Collins, Edith Milanzi, John O'Rourke

Journal of the International AIDS Society 2022;25(11):e25970

Free Full Text

Abstract

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial.

Alan Winston, Saye Khoo, Adriano Boasso, Dietmar Fuchs, Carolina Herrera, Maryam Khan, Jonathan Underwood, Jaime H Vera, Borja Mora-Peris, Michael R Keegan, Sujan Dilly Penchala

HIV research & clinical practice 2022;22(6):151-159

Full Text

Abstract

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Francesca Ceccherini-Silberstein, Kurt Van Baelen, Daniele Armenia, Maria Trignetti, Evelien Rondelez, Lavinia Fabeni, Fernanda Scopelliti, Michela Pollicita, Liesbeth Van Wesenbeeck, Veerle Van Eygen, Luca Dori, Loredana Sarmati, Stefano Aquaro, Guido Palamara, Massimo Andreoni, Lieven J Stuyver, Carlo Federico Perno

Antimicrobial agents and chemotherapy 2010;54(9):3938-48

Free Full Text

Abstract

HIV resistance to raltegravir.

Francois Clavel

European journal of medical research 2010;14 Suppl 3(Suppl 3):47-54

Free Full Text

Abstract

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Andrea Calcagno, Antonio D'Avolio, Stefano Bonora

Expert opinion on drug metabolism & toxicology 2016;11(7):1167-76

Full Text

Abstract

Metabolic Consequences of Antiretroviral Therapy.

Janet Lo, Samuel C Russo, Caroline E Diggins

Current HIV/AIDS reports 2022;19(2):141-153

Full Text

Abstract

Results: 1 – 15 / 206

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""HIV Integrase Inhibitors""[mesh_terms]

Raltegravir penetration in seminal plasma of healthy volunteers.

A safety evaluation of raltegravir for the treatment of HIV.

The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience.

Integrase strand transfer inhibitors, their impact in adipose tissue and weight gain in people living with HIV - A narrative review.

Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.

Targeting the HIV integration process in antiviral therapy.

Raltegravir in treatment naive patients.

Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches.

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

HIV resistance to raltegravir.

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Metabolic Consequences of Antiretroviral Therapy.

Results for
""HIV Integrase Inhibitors""[mesh_terms]